EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SK Bioscience Co's enterprise value is ₩3,225,490 Mil.
SK Bioscience Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₩43,490 Mil. Therefore, SK Bioscience Co's EV-to-EBITDA for today is 74.17.
The historical rank and industry rank for SK Bioscience Co's EV-to-EBITDA or its related term are showing as below:
XKRX:302440'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.65 Med: 53.77 Max: 179.97
Current: 74.17
During the past 6 years, the highest EV-to-EBITDA of SK Bioscience Co was 179.97. The lowest was 10.65. And the median was 53.77.
XKRX:302440's EV-to-EBITDA is ranked worse than 92.62% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs XKRX:302440: 74.17
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-25), SK Bioscience Co's stock price is ₩58300.00.
SK Bioscience Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩288.000. Therefore, SK Bioscience Co's PE Ratio for today is 202.43.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
SK Bioscience Co EV-to-EBITDA Historical Data
The historical data trend for SK Bioscience Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of SK Bioscience Co's EV-to-EBITDA
For the Biotechnology subindustry, SK Bioscience Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SK Bioscience Co's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SK Bioscience Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SK Bioscience Co's EV-to-EBITDA falls into.
SK Bioscience Co EV-to-EBITDA Calculation
SK Bioscience Co's EV-to-EBITDA for today is calculated as:
SK Bioscience Co's current Enterprise Value is ₩3,225,490 Mil.
SK Bioscience Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩43,490 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SK Bioscience Co (XKRX:302440) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
SK Bioscience Co's PE Ratio for today is calculated as:
SK Bioscience Co's share price for today is ₩58300.00.
SK Bioscience Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩288.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of SK Bioscience Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
SK Bioscience Co (XKRX:302440) Business Description
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:302440 has been successfully added to your 